The award was announced to examine a question for which controlled evidence was limited: whether selected cannabis components could affect pain and associated symptoms during an acute migraine attack.
The research question
The planned study compared three vaporized formulations—CBD, THC, and a CBD–THC combination—with placebo. Its design was intended to assess changes in pain intensity, light sensitivity, sound sensitivity, and nausea, while also monitoring psychoactive and other adverse effects.
At the time of the announcement, this three-year project was presented as a controlled investigation rather than proof of safety or effectiveness. Randomization, blinding, and placebo comparison were important because they can reduce bias and help researchers distinguish treatment effects from expectation and natural symptom fluctuation.
Symptoms included in the study
Migraine attacks can involve more than head pain. The proposed outcomes therefore included photophobia, phonophobia, and nausea alongside pain intensity. Examining several outcomes can provide a fuller view of whether an intervention changes the overall attack experience.
Why controlled evidence was needed
People had reported using cannabis products for migraine, but individual experiences could not establish which compound, dose, or formulation might be helpful or harmful. Products may differ substantially, and uncontrolled reports cannot reliably separate benefit, risk, expectation, and other influences.
The project aimed to create more structured evidence. As with any study, its findings would need to be interpreted in light of the enrolled population, protocol, sample size, endpoints, adverse events, and subsequent research. Results from a specific vaporized formulation should not automatically be generalized to other products or routes of administration.
Putting this announcement in context
This page preserves the central purpose of the 2018 announcement while removing promotional claims and time-sensitive legal assertions. Laws, product regulation, and clinical evidence can change. Readers seeking current treatment information should review the migraine treatment overview and consult an appropriately qualified healthcare professional.